Skip to main content
Top
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer

Authors: Ning Su, Liang Peng, Bingqing Xia, Yingying Zhao, Angao Xu, Jing Wang, Xinying Wang, Bo Jiang

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background and aim

CD24 expression is associated with human colorectal cancer (CRC). Our previous data indicated that CD24 promoted the proliferation and invasion of colorectal cancer cells through the activation of ERK1/2. Since Src family kinases are frequently deregulated in CRC and closely related to the MAPK signaling pathway, we investigated the impact of Lyn, an important member of SFKs, on CD24-induced ERK1/2 activation in CRC.

Methods and Results

The interaction of CD24 and Lyn was identified by co-immunoprecipitation (Co-IP) and ectopic expression of CD24-induced Lyn activation. Inhibition of Lyn activation by phosphatase PP2 in SW480CD24cells abrogated CD24-induced invasion. The results of the Co-IP and immunofluorescence assay revealed that overexpression of CD24 enhanced the interaction of Lyn and ERK1/2 and induced the nuclear translocation of Lyn. However, inhibition of Lyn activity attenuated CD24-induced ERK1/2 activation, and depletion of CD24 disrupted Lyn-ERK1/2 interaction. Immunohistochemistry analysis for 202 cases of CRC showed that the expression of both CD24 and Lyn was positively correlated with tumor grade, stage, lymph node and distant metastasis. Patients with lower expression of CD24 or Lyn had a higher survival rate. The Cox multivariate analysis showed that CD24 expression, but not Lyn expression, was an independent prognostic factor of CRC.

Conclusions

Our results suggest that Lyn is involved in CD24-induced ERK1/2 activation in CRC. The expression of CD24 is associated with activation of Lyn and ERK1/2, which might be a novel mechanism related to CD24-mediated regulation of CRC development.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kristiansen G, Sammar M, Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004, 35: 255-262.CrossRefPubMed Kristiansen G, Sammar M, Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004, 35: 255-262.CrossRefPubMed
2.
go back to reference Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 2003, 9: 4906-4913.PubMed Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 2003, 9: 4906-4913.PubMed
3.
go back to reference Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004, 58: 183-192. 10.1002/pros.10324CrossRefPubMed Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004, 58: 183-192. 10.1002/pros.10324CrossRefPubMed
4.
go back to reference Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF: CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007, 11: 445-451. 10.1007/s11605-007-0091-5PubMedCentralCrossRefPubMed Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF: CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007, 11: 445-451. 10.1007/s11605-007-0091-5PubMedCentralCrossRefPubMed
5.
go back to reference Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol. 2007, 14: 2748-2758. 10.1245/s10434-007-9501-xCrossRefPubMed Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol. 2007, 14: 2748-2758. 10.1245/s10434-007-9501-xCrossRefPubMed
6.
go back to reference Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N: CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006, 131: 630-639. 10.1053/j.gastro.2006.04.028CrossRefPubMed Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N: CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006, 131: 630-639. 10.1053/j.gastro.2006.04.028CrossRefPubMed
7.
go back to reference Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H, Jiang B: CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2010, 101: 112-119. 10.1111/j.1349-7006.2009.01370.xCrossRefPubMed Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H, Jiang B: CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2010, 101: 112-119. 10.1111/j.1349-7006.2009.01370.xCrossRefPubMed
8.
go back to reference Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D: The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 2006, 66: 1917-1922. 10.1158/0008-5472.CAN-05-3855CrossRefPubMed Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D: The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 2006, 66: 1917-1922. 10.1158/0008-5472.CAN-05-3855CrossRefPubMed
9.
go back to reference Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G, Altevogt P: CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis. 2011 Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G, Altevogt P: CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis. 2011
10.
go back to reference Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P: The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000, 60: 6714-6722.PubMed Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P: The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000, 60: 6714-6722.PubMed
11.
go back to reference Chen GY, Tang J, Zheng P, Liu Y: CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009, 323: 1722-1725. 10.1126/science.1168988PubMedCentralCrossRefPubMed Chen GY, Tang J, Zheng P, Liu Y: CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009, 323: 1722-1725. 10.1126/science.1168988PubMedCentralCrossRefPubMed
12.
go back to reference Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA: Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun. 1996, 225: 384-391. 10.1006/bbrc.1996.1184CrossRefPubMed Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA: Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun. 1996, 225: 384-391. 10.1006/bbrc.1996.1184CrossRefPubMed
13.
go back to reference Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP: CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci. 2011 Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP: CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci. 2011
14.
go back to reference Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R: The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med. 1995, 181: 1827-1834. 10.1084/jem.181.5.1827CrossRefPubMed Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R: The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med. 1995, 181: 1827-1834. 10.1084/jem.181.5.1827CrossRefPubMed
15.
go back to reference Bjorge JD, Jakymiw A, Fujita DJ: Selected glimpses into the activation and function of Src kinase. Oncogene. 2000, 19: 5620-5635. 10.1038/sj.onc.1203923CrossRefPubMed Bjorge JD, Jakymiw A, Fujita DJ: Selected glimpses into the activation and function of Src kinase. Oncogene. 2000, 19: 5620-5635. 10.1038/sj.onc.1203923CrossRefPubMed
17.
go back to reference Janas ML, Hodgkin P, Hibbs M, Tarlinton D: Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J Immunol. 1999, 163: 4192-4198.PubMed Janas ML, Hodgkin P, Hibbs M, Tarlinton D: Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J Immunol. 1999, 163: 4192-4198.PubMed
18.
go back to reference Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR: LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010, 70: 2296-2306. 10.1158/0008-5472.CAN-09-3141PubMedCentralCrossRefPubMed Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR: LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010, 70: 2296-2306. 10.1158/0008-5472.CAN-09-3141PubMedCentralCrossRefPubMed
19.
go back to reference Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE: Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008, 68: 3323-3333. 10.1158/0008-5472.CAN-07-2997CrossRefPubMed Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE: Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008, 68: 3323-3333. 10.1158/0008-5472.CAN-07-2997CrossRefPubMed
20.
go back to reference Montero JC, Seoane S, Ocana A, Pandiella A: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011, 17: 5546-5552. 10.1158/1078-0432.CCR-10-2616CrossRefPubMed Montero JC, Seoane S, Ocana A, Pandiella A: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011, 17: 5546-5552. 10.1158/1078-0432.CCR-10-2616CrossRefPubMed
21.
go back to reference Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, Li JL, Ding YQ, Li JM: A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010, 220: 475-489.PubMed Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, Li JL, Ding YQ, Li JM: A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010, 220: 475-489.PubMed
22.
go back to reference Sammar M, Aigner S, Altevogt P: Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta. 1997, 1337: 287-294. 10.1016/S0167-4838(96)00177-XCrossRefPubMed Sammar M, Aigner S, Altevogt P: Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta. 1997, 1337: 287-294. 10.1016/S0167-4838(96)00177-XCrossRefPubMed
23.
go back to reference Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P: Mouse CD24 as a signaling molecule for integrin-mediated cell binding: functional and physical association with src-kinases. Biochem Biophys Res Commun. 1997, 234: 330-334. 10.1006/bbrc.1997.6639CrossRefPubMed Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P: Mouse CD24 as a signaling molecule for integrin-mediated cell binding: functional and physical association with src-kinases. Biochem Biophys Res Commun. 1997, 234: 330-334. 10.1006/bbrc.1997.6639CrossRefPubMed
24.
go back to reference Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J: CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. 2001, 166: 5567-5577.CrossRefPubMed Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J: CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. 2001, 166: 5567-5577.CrossRefPubMed
25.
go back to reference Mierke CT, Bretz N, Altevogt P: Contractile Forces Contribute to Increased Glycosylphosphatidylinositol-anchored Receptor CD24-facilitated Cancer Cell Invasion. J Biol Chem. 2011, 286: 34858-34871. 10.1074/jbc.M111.245183PubMedCentralCrossRefPubMed Mierke CT, Bretz N, Altevogt P: Contractile Forces Contribute to Increased Glycosylphosphatidylinositol-anchored Receptor CD24-facilitated Cancer Cell Invasion. J Biol Chem. 2011, 286: 34858-34871. 10.1074/jbc.M111.245183PubMedCentralCrossRefPubMed
26.
go back to reference Hayakawa F, Naoe T: SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci. 2006, 1086: 213-222. 10.1196/annals.1377.002CrossRefPubMed Hayakawa F, Naoe T: SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci. 2006, 1086: 213-222. 10.1196/annals.1377.002CrossRefPubMed
27.
go back to reference Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep. 2009, 22: 1149-1156.PubMed Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep. 2009, 22: 1149-1156.PubMed
28.
go back to reference Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 2005, 11: 6574-6581. 10.1158/1078-0432.CCR-05-0606CrossRefPubMed Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 2005, 11: 6574-6581. 10.1158/1078-0432.CCR-05-0606CrossRefPubMed
29.
go back to reference Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D: CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011, 71: 3802-3811. 10.1158/0008-5472.CAN-11-0519PubMedCentralCrossRefPubMed Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D: CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011, 71: 3802-3811. 10.1158/0008-5472.CAN-11-0519PubMedCentralCrossRefPubMed
30.
go back to reference Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N: Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008, 68: 2803-2812. 10.1158/0008-5472.CAN-07-6463CrossRefPubMed Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N: Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008, 68: 2803-2812. 10.1158/0008-5472.CAN-07-6463CrossRefPubMed
31.
go back to reference Shapira S, Shapira A, Starr A, Kazanov D, Kraus S, Benhar I, Arber N: An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology. 2011, 140: 935-946. 10.1053/j.gastro.2010.12.004CrossRefPubMed Shapira S, Shapira A, Starr A, Kazanov D, Kraus S, Benhar I, Arber N: An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology. 2011, 140: 935-946. 10.1053/j.gastro.2010.12.004CrossRefPubMed
32.
go back to reference Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M: CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol. 2009, 62: 1117-1122. 10.1136/jcp.2009.069310CrossRefPubMed Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M: CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol. 2009, 62: 1117-1122. 10.1136/jcp.2009.069310CrossRefPubMed
33.
go back to reference Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009, 15: 2258-2264. 10.3748/wjg.15.2258PubMedCentralCrossRefPubMed Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009, 15: 2258-2264. 10.3748/wjg.15.2258PubMedCentralCrossRefPubMed
34.
go back to reference Wang X, Li M, Wang J, Yeung CM, Zhang H, Kung HF, Jiang B, Lin MC: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol. 2006, 71: 1540-1550. 10.1016/j.bcp.2006.02.011CrossRefPubMed Wang X, Li M, Wang J, Yeung CM, Zhang H, Kung HF, Jiang B, Lin MC: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol. 2006, 71: 1540-1550. 10.1016/j.bcp.2006.02.011CrossRefPubMed
35.
go back to reference Yamaguchi N, Nakayama Y, Urakami T, Suzuki S, Nakamura T, Suda T, Oku N: Overexpression of the Csk homologous kinase (Chk tyrosine kinase) induces multinucleation: a possible role for chromosome-associated Chk in chromosome dynamics. J Cell Sci. 2001, 114: 1631-1641.PubMed Yamaguchi N, Nakayama Y, Urakami T, Suzuki S, Nakamura T, Suda T, Oku N: Overexpression of the Csk homologous kinase (Chk tyrosine kinase) induces multinucleation: a possible role for chromosome-associated Chk in chromosome dynamics. J Cell Sci. 2001, 114: 1631-1641.PubMed
36.
go back to reference Lee EJ, Seo SR, Um JW, Park J, Oh Y, Chung KC: NF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1. J Biol Chem. 2008, 283: 3392-3400.CrossRefPubMed Lee EJ, Seo SR, Um JW, Park J, Oh Y, Chung KC: NF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1. J Biol Chem. 2008, 283: 3392-3400.CrossRefPubMed
37.
go back to reference Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47: 3239-3245.PubMed Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47: 3239-3245.PubMed
38.
go back to reference Jin SH, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, Yuasa Y: IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer. 2008, 122: 1040-1046.CrossRefPubMed Jin SH, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, Yuasa Y: IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer. 2008, 122: 1040-1046.CrossRefPubMed
Metadata
Title
Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer
Authors
Ning Su
Liang Peng
Bingqing Xia
Yingying Zhao
Angao Xu
Jing Wang
Xinying Wang
Bo Jiang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-43

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine